Key result
Thyroid replacement therapy (OR 6.10; 95% CI 2.73-15.05) and history of malignancy (OR 3.76; 95% CI 1.47-10.43) emerged as novel risk factors for chronic thromboembolic pulmonary hypertension.
Why the study?
What are the risk factors associated with chronic thromboembolic pulmonary hypertension compared to nonthromboembolic pulmonary arterial hypertension?
Population
687 patients assessed at the time of diagnosis between 1996 and 2007, comprising prevalent chronic…
Comparison
Presence of potential risk factors vs Nonthromboembolic pre-capillary pulmonary…
Design
Cohort
Authors
Loading...
Identified novel CTEPH associations including thyroid replacement and malignancy; hypothesis-generating and requires prospective validation before guiding risk stratification.
Cohort (n=687)
Yes
What are the risk factors associated with chronic thromboembolic pulmonary hypertension compared to nonthromboembolic pulmonary arterial hypertension?
Odds Ratio: 6.1 (95% CI 2.73–15.05)
Thyroid replacement therapy and a history of malignancy are newly identified medical conditions associated with an increased risk of chronic thromboembolic pulmonary hypertension.
Bonderman et al. (2008) conducted a cohort in Chronic thromboembolic pulmonary hypertension (n=687). Thyroid replacement therapy and history of malignancy vs. Patients with nonthromboembolic pre-capillary pulmonary arterial hypertension was evaluated on Association with chronic thromboembolic pulmonary hypertension (OR 6.10, 95% CI 2.73-15.05). Thyroid replacement therapy (OR 6.10; 95% CI 2.73-15.05) and history of malignancy (OR 3.76; 95% CI 1.47-10.43) emerged as novel risk factors for chronic thromboembolic pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: